ICH consults on format for periodic benefit-risk reporting for marketed drugs
This article was originally published in SRA
Executive Summary
The International Conference on Harmonisation has issued for stakeholder consultation a common standard for the periodic reporting by drug companies of the benefit-risk profile of their marketed products, including approved drugs that are under further study1,2.